Abstract:The ubiquitin-proteasome system (UPS) is a catalytic machinery that targets numerous cellular proteins for degradation, thus being essential to control a wide range of basic cellular processes and cell survival. Degradation of intracellular proteins via the UPS is a tightly regulated process initiated by tagging a target protein with a specific ubiquitin chain. Neurons are particularly vulnerable to any change in protein composition, and therefore the UPS is a key regulator of neuronal physiology. Alterations in UPS activity may induce pathological responses, ultimately leading to neuronal cell death. Brain ischemia triggers a complex series of biochemical and molecular mechanisms, such as an inflammatory response, an exacerbated production of misfolded and oxidized proteins, due to oxidative stress, and the breakdown of cellular integrity mainly mediated by excitotoxic glutamatergic signaling. Brain ischemia also damages protein degradation pathways which, together with the overproduction of damaged proteins and consequent upregulation of ubiquitin-conjugated proteins, contribute to the accumulation of ubiquitin-containing proteinaceous deposits. Despite recent advances, the factors leading to deposition of such aggregates after cerebral ischemic injury remain poorly understood. This review discusses the current knowledge on the role of the UPS in brain function and the molecular mechanisms contributing to UPS dysfunction in brain ischemia with consequent accumulation of ubiquitin-containing proteins. Chemical inhibitors of the proteasome and small molecule inhibitors of deubiquitinating enzymes, which promote the degradation of proteins by the proteasome, were both shown to provide neuroprotection in brain ischemia, and this apparent contradiction is also discussed in this review.

The Ubiquitin Proteasome System As a Potential Target for the Treatment of Neurodegenerative Diseases

Exploring the Role of Ubiquitin-Proteasome System in the Pathogenesis of Parkinson's Disease

Role of the ubiquitin–proteasome system in brain ischemia: Friend or foe?

Exploration on the Mechanism of Ubiquitin Proteasome System in Cerebral Stroke

Modulating the Ubiquitin–Proteasome System: A Therapeutic Strategy for Autoimmune Diseases

Mechanistic exploration of ubiquitination-mediated pathways in cerebral ischemic injury

Recent pharmacological insights on abating toxic protein species burden in neurological disorders: Emphasis on 26S proteasome activation

Neurodevelopmental Disorders (NDD) Caused by Genomic Alterations of the Ubiquitin-Proteasome System (UPS): the Possible Contribution of Immune Dysregulation to Disease Pathogenesis

ER stress and the unfolded protein response in neurodegeneration

Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention

The Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer’s Disease

Drugging the undruggables: exploring the ubiquitin system for drug development

The role of ubiquitin proteasomal system and autophagy-lysosome pathway in Alzheimer’s disease

Ubiquitin–proteasome system (UPS) as a target for anticancer treatment

Disrupted ubiquitin proteasome system underlying tau accumulation in Alzheimer’s disease

Deubiquitinating enzymes (DUBs): decipher underlying basis of neurodegenerative diseases

Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers

Copper Homeostasis and the Ubiquitin Proteasome System

Targeting the Ubiquitin-Proteasome System and Recent Advances in Cancer Therapy

Does neurotrophic factor benefit to PD therapy via co-function with ubiquitin-proteasome system?

Person‐specific differences in ubiquitin‐proteasome mediated proteostasis in human neurons